Refine your search
Collections
Co-Authors
Journals
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All
Ashawat, M. S.
- Post-Marketing Surveillance Studies on the Paediatric population Associated with Vaccination
Abstract Views :251 |
PDF Views:2
Authors
N. K. Hada
1,
M. S. Ashawat
1
Affiliations
1 Laureate Institute of Pharmacy, Kathog, Hamirpur, Himachal Pradesh, IN
1 Laureate Institute of Pharmacy, Kathog, Hamirpur, Himachal Pradesh, IN
Source
Research Journal of Pharmacology and Pharmacodynamics, Vol 6, No 1 (2014), Pagination: 50-58Abstract
The aim of this text is to grasp the requirement of observance and coverage of the adverse events (AEs) related to vaccination throughout the post-marketing surveillance studies (PMS) and analysis of the protection, efficaciousness and adverse events of vaccination data from PMS studies. The data obtained through numerous specialists with moral pointers of medicine vaccination by knowing the severity of AEs. Literature review and survey form were key aspects for the achieving the objectives. The approval for the survey form obtained from ICRI (India). The analysis work would be helpful for the scholars UN agency area unit wanting to recognize the particular state of affairs of vaccination associated adverse events and additionally knowledgeable to induce some necessary facts regarding AEs observance in children's once vaccination. For the health professionals it'd create them tuned in to their role and responsibilities in surveillance system. Parents of such subjects were also informing the way to beware of their children's vaccination schedules and management of delicate adverse drug reaction and events.Aim and Objecive: The aim of the research is to identify the importance of monitoring and reporting of AEs associated with vaccination during the PMS studies and evaluation of the safety, efficacy and adverse events of vaccination by comparing data from PMS studies obtained through various paediatricians with ethical guidelines on paediatric in different countries across the worldwide.
Methodology: Research work has been conducted after an extensive review of literature. With help of questionnaire, a survey among various paediatricians has been conducted. Then data collection on the basis of obtained by these paediatricians has been done. Analysis and compiling of obtained data is done. Results obtained with the help of statistical methods.
Results: Obtained results from the questionnaires survey demonstrate that 70% of paediatricians reported vaccines available for paediatrics are essential, while remaining 30% are not in the favour of all vaccines use and only recommend vaccines according to their experience and NIS (National Immunization Schedule). 60% of paediatricians reported AEs associated with vaccination are mild, 32% reported these AEs moderate, and 8% reported these AEs are severe. Hospitalization is not recommended by any of above paediatricians. 76% of paediatricians prefer treatment for AEs at home only, while 66% are not aware of the any AEs monitoring and reporting system.
Conclusion: Awareness of the AEs monitoring, reporting and management is necessary among the health professionals and parents. Awareness campaign should be conducted to report and management of AEs associated with vaccination in paediatrics. The passive system needs to be getting active so the short comings of passive system will overcome. Common case definitions and guidelines are required globally so uniformity in reporting the ADRs and AEs will be achieved.
References
- Kari S. Lankinen, Satu Pastila, Patrick Olin ; "Vaccinnovigillance in Europe-need for timeliness, standardization and resources"; Bulletin of the World Health Organization; November 2004, 82 (11), Page No. 828-835.
- K.D. Tripathi, "Essentials of Medical Pharmacology"; 5th Edition, Page No. 827-835.
- Standard Operating Procedures for Investigations of Adverse Events Following Immunization"; Department of Family Welfare, Ministry Of Health and Family Welfare, Government of India, Page No. 6-38.
- Kathleen Meister, M.S.,"Vaccination: What Parents Need To Know"; Sep.2003:1-24.
- "Guidelines for Reporting Adverse Events Associated with Vaccine Products"; Feb.2000, Volume 26S1, Page No. 1-22.
- Jan Bonhoeffer, Kartin Kohl, Robert Chen; " The Brighton Collaboration: Addressing The Need For Standardized Case Definitions Of Adverse Events Following Immunization (AEFI)" ; Vaccine 21 (2002) 298-302.
- "The development of standardized Case Definitions and guidelines for Adverse Events Following Immunization" ; Vaccine 25(2005) 5671-5674.
- L. C. Rodrigues and P. G. Smith; " Use of the Case - Control Approach in Vaccine Evaluation: Efficacy and Adverse Effects"; Vol. 21, No. 1, 1999.
- S. Michael Marcy, "Fever as an Adverse Events Following Immunization: Case Definition and Guidelines for Collection, Analysis, and Presentation "Vaccine 22 (2004), 2091-2095.
- Alberto E. Tozzi, " Field Evaluation of Vaccine safety"; Vaccine 22, (2004), 2091-2095
- John Beigel, Floyd Brintly et all; " generalized vaccininia as an Adverse Events Following exposure to Vaccinia Case Definition and Guidelines for collection, Analysis and presentation of immunization safety data" ; Vaccine 25,(2007), 5745-5753.
- Philip Duclos, "Global perspective on vaccine safety"; Vaccine 22 (2004), 2059-2063.
- Robert Menzies 1 and Peter Mc Intyre, "Vaccine Preventable Diseases and Vaccination Policy for Indigenous Populations" Vol. 28, 2006: 71-80.
- "Adverse Drug Reaction Monitoring in Pediatric practice"; Indian Pediatrics Volume 33, December 1996, 993-998.
- Maria Luisa Avila. et all; " Immunology And Tolerability Of Inactivated Flu Vaccine In High Risk And Healthy Children"; Medicina , Volume 67, No 4, 2007, 351-359.
- Sandeep B. Bavdekar, Sunil Karande, "National Pharmacovigillance Program"; Indian Pediatrics, Volume 42, January 17, 2006, 27-32.
- Neil Z. Miller, " The Polio vaccine: A Critical Assessment Of Its Arcane History, Efficacy, And Long- Term Health - Related Consequences"; Volume 1 (2004) 239-251.
- John Beigl, katrin S. Kohl, Lulu Bravo et all; " Rash Including Mucosal Involvement: Case Definition And Guidelines For Collection, Analysis, And Presentation Of Immunization Safety Data"; vaccine 25 (2007) 5697-5706.
- Janie Parrino, MD, and Barney S. Graham, MD, PhD; "Smallpox Vaccines: Past, Present, and Future"; Volume 118, Number 6, 1320-1326.
- Ville Postila, Terhi Kilpi, "Use of Vaccine Surveillance data in the evalution of safety of vaccines"; Vaccine 22 (2004) 2076-2079.
- Katrin S. Kohl, Wikke Walop at all; " swelling at or near injection site: Case definition and Guidelines for Collection, Analysis, and Presentation of Immunization safety data" ; Vaccine 25 (2007) 5858-5874.
- Marc girard, M.D., MSc., "World Health Organization Vaccine Recommendations: Scientific Flaws, or Criminal Misconduct" ; Journal of American Physicians and Surgeons, Volume 11, Number 1, Spring 2006, 22-23.
- Nichols Wood,David Isaacs,"Monitoring Vaccine Reaction in Australia" MJA,Vol;184, No;4
- Journal of American Physicians and Surgeons, Volume 11, Number 1, spring 2006, 8-13.
- Robert T. chen, Evalution of Vaccine safety after the events of 11 September 2001 : role of cohort and case - control studies" ; Vaccines 22 (2004) 2047-2053.
- Reza Imani et al;"Adverse Events Following Measles and Rubella Immunization Campaign in Shahrekord, Iran; 2003-04"; Kuwait medical journal 2007,39 (4): 327-329.
- A.M. Galazka, S. E. Robertson, et all; "Mumps and mumps vaccine: A global review"; Bulletin of the World Health Organization, 1999, 77, 3-14.
- J. Michael Lane, Joel Goldstein,FAAP; "Adverse Events Occuring after Smallpox Vaccination"; Seminars in Pediatric Infectious Diseases, Vol 14, no 3 (July), 2003:189-195.
- Efficacy of Diversified Therapeutics Agents in the Management of Peripheral Neuropathy
Abstract Views :204 |
PDF Views:0
Authors
Affiliations
1 Rungta College of Pharmaceutical Sciences and Research, Bhilai CG, IN
1 Rungta College of Pharmaceutical Sciences and Research, Bhilai CG, IN
Source
Asian Journal of Research in Pharmaceutical Sciences, Vol 3, No 4 (2013), Pagination: 151-160Abstract
Peripheral neuropathy is caused either by diseases or trauma to the nerve or the side effects of systemic illness or due to the neurotoxicity and due to some drugs as a side effect. Owing to peripheral neuropathy, patients suffer from neuropathic pain. In this review author strive to gathered succinct literature on diversified therapeutic agents used for the treatment of neuropathic pain, with and without clinically proven efficacy for the nerve repair. Some herbal remedies also claimed to have the nerve repair properties with a little significant data. Many synthetic agents like methylcobalamin, thiamine many anti-convulsant, neuromuscular blocking agents, are being used for treating pain. The remedies like Vitamin D, B vitamins, vitamin B6, Vitamin B12, St. John's Wort, fish oil, Cannabinoids, Opioids, etc. Controlling the underlying disease process and treating troublesome symptoms are the basic goals of the treatment. This review explains how to revive the neuropathy symptoms, diagnostic approaches, and the conventional as well as alternative approaches for the treatment.Keywords
Peripheral Neuropathy, Nerve Trauma, Neurotoxicity, Neuropathic Pain.- Aquasome: A Self-Assembling Supramolecular And Nanoparticulate Carrier System For Bio-Actives
Abstract Views :162 |
PDF Views:0
Authors
N. K. Hada
1,
M. S. Ashawat
1
Affiliations
1 Laureate Institute of Pharmacy, Kathog, Hamirpur, Himachal Pradesh, IN
1 Laureate Institute of Pharmacy, Kathog, Hamirpur, Himachal Pradesh, IN
Source
Research Journal of Pharmaceutical Dosage Form and Technology, Vol 6, No 1 (2014), Pagination: 50-53Abstract
Recent advancement within the space of biotechnology and genetics science has resulted in promotion of proteins and peptides as a major class of therapeutic agents. Administration of the bioactive molecules in their active state has been an enormous task to the pharmaceutical additionally as biotechnological industries. Drug associated challenges like appropriate route of drug delivery, physical and chemical instability, poor bioavailability, and potentially serious side effects of these bioengineered molecules are some potential limitations on their successful formulation. While developing these formulations, the goal is to obtain delivery system with optimized drug loading and release properties, long shelf-life and low toxicity. Several types of NDDS have been developed for last few decades which are aquasome, liposomes, niosomes, pharmacosomes, microparticles, nanoparticles, dendrimers, multiple emulsions, microemulsions, osmotic-modulated drug delivery system, transdermal-therapeutic system, self-regulated and braintargated drug delivery system etc. consider as promising carrier for the delivery of a broad range of molecules includes xenobiotics, viral antigens, haemoglobin and insulin. Whereever medicine area allowed to absorb on the surface of nanoparticales within the presence of carbohydrates film that prevent soft drugs from changing shaped and being damaged when surface bound.Keywords
Water Bodies, Self-Assembling Carrier System, Nano Particulate , Nanocrystalline Core, Supramolecule, Bio-Actives Etc.- Promising Development in Vaginal Drug Delivery: Recent Advances for Peptide and Protein Drug Delivery
Abstract Views :157 |
PDF Views:0
Authors
Affiliations
1 Rungta College of Pharmaceutical Sciences and Research, Bhilai, CG, IN
1 Rungta College of Pharmaceutical Sciences and Research, Bhilai, CG, IN
Source
Research Journal of Pharmaceutical Dosage Form and Technology, Vol 5, No 6 (2013), Pagination: 378-384Abstract
Extensive efforts have been made to the administration of drugs, via alternative routes, that are poorly absorbed after the oral administration. The vaginal route of drug delivery has been known since ancient times for gynecological disorder. Traditional drug delivery systems for vaginal and oral application have employed waxes, oils, natural macromolecules, and a relatively small number of water-soluble and -insoluble synthetic polymers as critical formulation material. In recent years, the vaginal route has been experience again as a potential route for systemic delivery of special hormones and some anti-HIV and other therapeutically important macromolecules emerging with many smart and modified carrier systems are tried for gynecological disorder like Amenorrhea. However, successful delivery of drugs through the vagina remains a challenge, primarily due to the poor absorption across the vaginal epithelium. The rate and extent of drug absorption after intra vaginal administration may vary depending on formulation factors, vaginal physiology, age of the patient and menstrual cycle. The purpose of this review is to provide the reader with an awareness, diagnosis and possible treatment of Amenorrhea with summary of advances made in the field of vaginal drug delivery and provide an easy understanding of various vaginal drug delivery systems currently available in the market.Keywords
Intra-Vaginal, Amenorrhea, Hydrogel, Bioadhesive, Dendrimer Drug Delivery.- Application of Nanocarrier in Drug development with special Emphasis on Liposomes: A Review
Abstract Views :76 |
PDF Views:0
Authors
Anshul Sharma
1,
Keshav Dhiman
1,
Anshul Sharma
1,
Kamya Goyal
2,
Vinay Pandit
1,
M. S. Ashawat
1,
Shammy Jindal
1
Affiliations
1 Department of Pharmaceutics, Laureate Institute of Pharmacy, Kathog Jawalaji Dist - Kangra (H.P.), IN
2 Department of Pharmaceutical Analysis and Quality Assurance, Laureate Institute of Pharmacy, Kathog Jawalaji Dist - Kangra (H.P.), IN
1 Department of Pharmaceutics, Laureate Institute of Pharmacy, Kathog Jawalaji Dist - Kangra (H.P.), IN
2 Department of Pharmaceutical Analysis and Quality Assurance, Laureate Institute of Pharmacy, Kathog Jawalaji Dist - Kangra (H.P.), IN
Source
Asian Journal of Pharmacy and Technology, Vol 12, No 4 (2022), Pagination: 320-328Abstract
Liposomes are the nano-scale bilayer structure of phospholipid used as a carrier for a Large Variety of drugs. Both lipophilic and hydrophilic drugs can encapsulate into the liposome and delivered to the body. The purpose behind the preparation of liposomes is to reduce the side effects associated with systemic delivery of drugs as well as it also helps in the protection of biodegradable drugs and molecules such as protein and peptides from body enzymes and fluids. Other than these advantages liposome also have high skin permeation due to structural similarities with the stratum corneum and therefore can be used for the topical delivery of drugs. The various types of liposomes and their application in their marketed products are discussed below in the article.Keywords
Liposome, Gene Therapy, Theranostic ApplicationsReferences
- Gomez-Hens A, Fernández-Romero JM. The role of liposomes in analytical processes. TrAC Trends Anal Chem. 2005;24(1):9–19.
- Has C, Sunthar P. A comprehensive review on recent preparation techniques of liposomes. J Liposome Res. 2020;30(4):336–65.
- Manconi M, Caddeo C, Sinico C, Valenti D, Mostallino MC, Biggio G, et al. Ex vivo skin delivery of diclofenac by transcutol containing liposomes and suggested mechanism of vesicle–skin interaction. Eur J Pharm Biopharm. 2011;78(1):27–35.
- Mukherjee S, Ray S, Thakur RS. Solid lipid nanoparticles: a modern formulation approach in drug delivery system. Indian J Pharm Sci. 2009;71(4):349.
- Akhtar N. Vesicles: a recently developed novel carrier for enhanced topical drug delivery. Curr Drug Deliv. 2014;11(1):87–97.
- Jindal S, Awasthi R, Singare D, Kulkarni GT. Preparation and in vitro evaluation of Tacrolimus loaded liposomal vesicles by two methods: A comparative study. J Res Pharm. 2021;25(1):34–41.
- Chowdhury A, Kunjiappan S, Panneerselvam T, Somasundaram B, Bhattacharjee C. Nanotechnology and nanocarrier-based approaches on treatment of degenerative diseases. Int nano Lett. 2017;7(2):91–122.
- Siddiqi KS, Husen A, Sohrab SS, Yassin MO. Recent status of nanomaterial fabrication and their potential applications in neurological disease management. Nanoscale Res Lett. 2018;13(1):1–17.
- Yetisgin AA, Cetinel S, Zuvin M, Kosar A, Kutlu O. Therapeutic nanoparticles and their targeted delivery applications. Molecules. 2020;25(9):2193.
- Greish K, Fang J, Inutsuka T, Nagamitsu A, Maeda H. Macromolecular therapeutics. Clin Pharmacokinet. 2003;42(13):1089–105.
- Iyer AK, Khaled G, Fang J, Maeda H. Exploiting the enhanced permeability and retention effect for tumor targeting. Drug Discov Today. 2006;11(17–18):812–8.
- Nakamura H, Jun F, Maeda H. Development of next-generation macromolecular drugs based on the EPR effect: challenges and pitfalls. Expert Opin Drug Deliv. 2015;12(1):53–64.
- Çağdaş M, Sezer AD, Bucak S. Liposomes as potential drug carrier systems for drug delivery. Appl Nanotechnol drug Deliv. 2014;1:1–50.
- Ranade V V. Drug delivery systems. 1. Site‐specific drug delivery using liposomes as carriers. J Clin Pharmacol. 1989;29(8):685–94.
- Choudhury H, Gorain B, Pandey M, Chatterjee LA, Sengupta P, Das A, et al. Recent update on nanoemulgel as topical drug delivery system. J Pharm Sci. 2017;106(7):1736–51.
- Rahimpour Y, Hamishehkar H. Liposomes in cosmeceutics. Expert Opin Drug Deliv. 2012;9(4):443–55.
- Kaur IP, Kakkar S. Topical delivery of antifungal agents. Expert Opin Drug Deliv. 2010;7(11):1303–27.
- Li W, Joshi MD, Singhania S, Ramsey KH, Murthy AK. Peptide vaccine: progress and challenges. Vaccines. 2014;2(3):515–36.
- Gregory AE, Williamson D, Titball R. Vaccine delivery using nanoparticles. Front Cell Infect Microbiol. 2013;3:13.
- Tandrup Schmidt S, Foged C, Smith Korsholm K, Rades T, Christensen D. Liposome-based adjuvants for subunit vaccines: formulation strategies for subunit antigens and immunostimulators. Pharmaceutics. 2016;8(1):7.
- Khalaj‐Hedayati A, Chua CLL, Smooker P, Lee KW. Nanoparticles in influenza subunit vaccine development: Immunogenicity enhancement. Influenza Other Respi Viruses. 2020;14(1):92–101.
- Li J, Wang X, Zhang T, Wang C, Huang Z, Luo X, et al. A review on phospholipids and their main applications in drug delivery systems. Asian J Pharm Sci. 2015;10(2):81–98.
- Singh RP, Gangadharappa H V, Mruthunjaya K. Phospholipids: Unique carriers for drug delivery systems. J Drug Deliv Sci Technol. 2017;39:166–79.
- Paltauf F, Hermetter A. Phospholipids—Natural, semisynthetic, synthetic. In: Phospholipids. Springer; 1990. p. 1–12.
- Ahmed KS, Hussein SA, Ali AH, Korma SA, Lipeng Q, Jinghua C. Liposome: Composition, characterisation, preparation, and recent innovation in clinical applications. J Drug Target. 2019;27(7):742–61.
- Silvius JR. Role of cholesterol in lipid raft formation: lessons from lipid model systems. Biochim Biophys Acta (BBA)-Biomembranes. 2003;1610(2):174–83.
- Harayama T, Riezman H. Understanding the diversity of membrane lipid composition. Nat Rev Mol cell Biol. 2018;19(5):281–96.
- Zhukovsky MA, Filograna A, Luini A, Corda D, Valente C. Phosphatidic acid in membrane rearrangements. FEBS Lett. 2019;593(17):2428–51.
- Iscaro A, Howard NF, Muthana M. Nanoparticles: properties and applications in cancer immunotherapy. Curr Pharm Des. 2019;25(17):1962–79.
- P Samy R, Gopalakrishnakone P, G Stiles B, S Girish K, N Swamy S, Hemshekhar M, et al. Snake venom phospholipases A2: a novel tool against bacterial diseases. Curr Med Chem. 2012;19(36):6150–62.
- Jindal S, Awasthi R, Singhare D, Kulkarni GT. Topical delivery of Tacrolimus using liposome containing gel: An emerging and synergistic approach in management of psoriasis. Med Hypotheses. 2020;142:109838.
- Medina OP, Zhu Y, Kairemo K. Targeted liposomal drug delivery in cancer. Curr Pharm Des. 2004;10(24):2981–9.
- Panahi Y, Farshbaf M, Mohammadhosseini M, Mirahadi M, Khalilov R, Saghfi S, et al. Recent advances on liposomal nanoparticles: synthesis, characterization and biomedical applications. Artif cells, nanomedicine, Biotechnol. 2017;45(4):788–99.
- Daraee H, Etemadi A, Kouhi M, Alimirzalu S, Akbarzadeh A. Application of liposomes in medicine and drug delivery. Artif cells, nanomedicine, Biotechnol. 2016;44(1):381–91.
- Jindal S, Kumar A, Goyal K, Awasthi R, Kulkarni GT. Lipid Nanocarriers for Dermal Delivery of Lutein. In: Nanomedicine for Bioactives. Springer; 2020. p. 341–66.
- Mura S, Nicolas J, Couvreur P. Stimuli-responsive nanocarriers for drug delivery. Nat Mater. 2013;12(11):991–1003.
- Huang Z, Li X, Zhang T, Song Y, She Z, Li J, et al. Progress involving new techniques for liposome preparation. asian J Pharm Sci. 2014;9(4):176–82.
- Mozafari MR. Liposomes: an overview of manufacturing techniques. Cell Mol Biol Lett. 2005;10(4):711.
- Paternostre MT, Roux M, Rigaud JL. Mechanisms of membrane protein insertion into liposomes during reconstitution procedures involving the use of detergents. 1. Solubilization of large unilamellar liposomes (prepared by reverse-phase evaporation) by triton X-100, octyl glucoside, and sodium. Biochemistry. 1988;27(8):2668–77.
- Edwards K, Johnsson M, Karlsson G, Silvander M. Effect of polyethyleneglycol-phospholipids on aggregate structure in preparations of small unilamellar liposomes. Biophys J. 1997;73(1):258–66.
- Kumar S, Kaur N, Mithu VS. Amphiphilic ionic liquid induced fusion of phospholipid liposomes. Phys Chem Chem Phys. 2020;22(43):25255–63.
- Zhang H. Thin-film hydration followed by extrusion method for liposome preparation. In: Liposomes. Springer; 2017. p. 17–22.
- Fernández-García R, Lalatsa A, Statts L, Bolás-Fernández F, Ballesteros MP, Serrano DR. Transferosomes as nanocarriers for drugs across the skin: Quality by design from lab to industrial scale. Int J Pharm. 2020;573:118817.
- Varona S, Martin A, Cocero MJ. Liposomal incorporation of lavandin essential oil by a thin-film hydration method and by particles from gas-saturated solutions. Ind Eng Chem Res. 2011;50(4):2088–97.
- Marsden HR, Gabrielli L, Kros A. Rapid preparation of polymersomes by a water addition/solvent evaporation method. Polym Chem. 2010;1(9):1512–8.
- Zhang X, Coleman AC, Katsonis N, Browne WR, Van Wees BJ, Feringa BL. Dispersion of graphene in ethanol using a simple solvent exchange method. Chem Commun. 2010;46(40):7539–41.
- Kim SW, Kim T, Kim YS, Choi HS, Lim HJ, Yang SJ, et al. Surface modifications for the effective dispersion of carbon nanotubes in solvents and polymers. Carbon N Y. 2012;50(1):3–33.
- Ming-Jie LI, ZHANG H-Y, Xiao-Zhe LIU, Chun-Yan CUI, Zhi-Hong SHI. Progress of extraction solvent dispersion strategies for dispersive liquid-liquid microextraction. Chinese J Anal Chem. 2015;43(8):1231–40.
- Chen J, Brooks III CL, Khandogin J. Recent advances in implicit solvent-based methods for biomolecular simulations. Curr Opin Struct Biol. 2008;18(2):140–8.
- Szoka F, Papahadjopoulos D. Procedure for preparation of liposomes with large internal aqueous space and high capture by reverse-phase evaporation. Proc Natl Acad Sci. 1978;75(9):4194–8.
- Mertins O, Sebben M, Pohlmann AR, da Silveira NP. Production of soybean phosphatidylcholine–chitosan nanovesicles by reverse phase evaporation: a step by step study. Chem Phys Lipids. 2005;138(1–2):29–37.
- Taylor KMG, Taylor G, Kellaway IW, Stevens J. Drug entrapment and release from multilamellar and reverse-phase evaporation liposomes. Int J Pharm. 1990;58(1):49–55.
- Trucillo P, Campardelli R, Reverchon E. Liposomes: From bangham to supercritical fluids. Processes. 2020;8(9):1022.
- Jung J, Perrut M. Particle design using supercritical fluids: literature and patent survey. J Supercrit Fluids. 2001;20(3):179–219.
- Naik S, Patel D, Surti N, Misra A. Preparation of PEGylated liposomes of docetaxel using supercritical fluid technology. J Supercrit Fluids. 2010;54(1):110–9.
- Xia F, Hu D, Jin H, Zhao Y, Liang J. Preparation of lutein proliposomes by supercritical anti-solvent technique. Food Hydrocoll. 2012;26(2):456–63.
- Booysen E. Characterization of a novel antibiotic isolated from Xenorhabdus khoisanae and encapsulation of vancomycin in nanoparticles. Stellenbosch: Stellenbosch University; 2018.
- Lesoin L, Crampon C, Boutin O, Badens E. Preparation of liposomes using the supercritical anti-solvent (SAS) process and comparison with a conventional method. J Supercrit Fluids. 2011;57(2):162–74.
- Kompella UB, Koushik K. Preparation of drug delivery systems using supercritical fluid technology. Crit Rev Ther Drug Carr Syst. 2001;18(2).
- Amoabediny G, Haghiralsadat F, Naderinezhad S, Helder MN, Akhoundi Kharanaghi E, Mohammadnejad Arough J, et al. Overview of preparation methods of polymeric and lipid-based (niosome, solid lipid, liposome) nanoparticles: A comprehensive review. Int J Polym Mater Polym Biomater. 2018;67(6):383–400.
- van Swaay D, DeMello A. Microfluidic methods for forming liposomes. Lab Chip. 2013;13(5):752–67.
- Yu B, Lee RJ, Lee LJ. Microfluidic methods for production of liposomes. Methods Enzymol. 2009;465:129–41.
- Amrani S. Microfluidic platform for the fabrication and loading of nanoscale liposomes by 2D hydrodynamic flow focusing. McGill University (Canada); 2018.
- Cheung C. Preparation of Multifunctional Nanoparticles Using Microfluidics. Queen’s University Belfast; 2020.
- Shum HC, Thiele J, Kim S-H. Microfluidic fabrication of vesicles. Adv Transp Phenom 2011. 2014;1–28.
- Hu PC, Li S, Malmstadt N. Microfluidic fabrication of asymmetric giant lipid vesicles. ACS Appl Mater Interfaces. 2011;3(5):1434–40.
- Vayssieres L, Keis K, Hagfeldt A, Lindquist S-E. Three-dimensional array of highly oriented crystalline ZnO microtubes. Chem Mater. 2001;13(12):4395–8.
- Ding X, Zeng D, Zhang S, Xie C. C-doped WO3 microtubes assembled by nanoparticles with ultrahigh sensitivity to toluene at low operating temperature. Sensors Actuators B Chem. 2011;155(1):86–92.
- Li Q, Wang X, Ma S, Zhang Y, Han X. Electroformation of giant unilamellar vesicles in saline solution. Colloids Surfaces B Biointerfaces. 2016;147:368–75.
- Stein H, Spindler S, Bonakdar N, Wang C, Sandoghdar V. Production of isolated giant unilamellar vesicles under high salt concentrations. Front Physiol. 2017;8:63.
- Kuribayashi K, Tresset G, Coquet P, Fujita H, Takeuchi S. Electroformation of giant liposomes in microfluidic channels. Meas Sci Technol. 2006;17(12):3121.
- Kanha N, Regenstein JM, Surawang S, Pitchakarn P, Laokuldilok T. Properties and kinetics of the in vitro release of anthocyanin-rich microcapsules produced through spray and freeze-drying complex coacervated double emulsions. Food Chem. 2021;340:127950.
- Kim TH, Park TG. Critical effect of freezing/freeze-drying on sustained release of FITC-dextran encapsulated within PLGA microspheres. Int J Pharm. 2004;271(1–2):207–14.
- Supramaniam P, Ces O, Salehi-Reyhani A. Microfluidics for artificial life: techniques for bottom-up synthetic biology. Micromachines. 2019;10(5):299.
- Monteiro N, Martins A, Reis RL, Neves NM. Liposomes in tissue engineering and regenerative medicine. J R Soc Interface. 2014;11(101):20140459.
- Xue J, Wu T, Dai Y, Xia Y. Electrospinning and electrospun nanofibers: Methods, materials, and applications. Chem Rev. 2019;119(8):5298–415.
- Mohanraj VJ, Chen Y. Nanoparticles-a review. Trop J Pharm Res. 2006;5(1):561–73.
- Jadhav SM, Morey P, Karpe M, Kadam V. Novel vesicular system: an overview. J Appl Pharm Sci. 2012;2(1):193–202.
- Narvekar M, Xue HY, Eoh JY, Wong HL. Nanocarrier for poorly water-soluble anticancer drugs—barriers of translation and solutions. Aaps Pharmscitech. 2014;15(4):822–33.
- Alam A, Farooq U, Singh R, Dubey VP, Kumar S, Kumari R, et al. Chemotherapy treatment and strategy schemes: A review. Open Access J Toxicol. 2018;2(5):555600.
- Pérez-Herrero E, Fernández-Medarde A. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy. Eur J Pharm Biopharm. 2015;93:52–79.
- Overchuk M, Zheng G. Overcoming obstacles in the tumor microenvironment: Recent advancements in nanoparticle delivery for cancer theranostics. Biomaterials. 2018;156:217–37.
- Lila ASA, Ishida T. Liposomal delivery systems: design optimization and current applications. Biol Pharm Bull. 2017;40(1):1–10.
- Sharma G, Anabousi S, Ehrhardt C, Ravi Kumar MN V. Liposomes as targeted drug delivery systems in the treatment of breast cancer. J Drug Target. 2006;14(5):301–10.
- Singh N, Sondhi S, Sharma S, Singh D, Koundal V, Goyal K, et al. Treatment of Skin Cancer by Topical Drug Delivery of Nanoparticles: A Review. Res J Pharm Technol. 2021;14(10):5589–98.
- Tamura A, Nagasaki Y. Smart siRNA delivery systems based on polymeric nanoassemblies and nanoparticles. Nanomedicine. 2010;5(7):1089–102.
- Mohammadinejad R, Dehshahri A, Madamsetty VS, Zahmatkeshan M, Tavakol S, Makvandi P, et al. In vivo gene delivery mediated by non-viral vectors for cancer therapy. J Control Release. 2020;325:249–75.
- Jindal S, Awasthi R, Singare D, Kulkarni GT. POTENTIAL OF HERBAL NANOCARRIER FORMULATION FOR THE TREATMENT OF PSORIASIS. Int J Pharm Life Sci. 2019;10(6).
- Goldberg M, Langer R, Jia X. Nanostructured materials for applications in drug delivery and tissue engineering. J Biomater Sci Polym Ed. 2007;18(3):241–68.
- Zhou J, Rossi JJ. Cell-specific aptamer-mediated targeted drug delivery. Oligonucleotides. 2011;21(1):1–10.
- Saad M, Garbuzenko OB, Minko T. Co-delivery of siRNA and an anticancer drug for treatment of multidrug-resistant cancer. 2008;
- Frezard F. Liposomes: from biophysics to the design of peptide vaccines. Brazilian J Med Biol Res. 1999;32(2).
- Nam G, Choi Y, Kim GB, Kim S, Kim SA, Kim I. Emerging prospects of exosomes for cancer treatment: from conventional therapy to immunotherapy. Adv Mater. 2020;32(51):2002440.
- Madni A, Sarfraz M, Rehman M, Ahmad M, Akhtar N, Ahmad S, et al. Liposomal drug delivery: a versatile platform for challenging clinical applications. J Pharm Pharm Sci. 2014;17(3):401–26.
- García A, De Sanctis JB. An overview of adjuvant formulations and delivery systems. Apmis. 2014;122(4):257–67.
- Du Y-F, Chen M, Xu J-R, Luo Q, Lu W-L. Preparation and Characterization of DNA Liposomes Vaccine. Liposome-Based Drug Deliv Syst. 2021;259–75.
- Sharma A, Anghore D, Awasthi R, Kosey S, Jindal S, Gupta N, et al. A review on current carbon nanomaterials and other nanoparticles technology and their applications in biomedicine. World J Pharm Pharm Sci. 2015;4(12):1088–113.
- Bozzuto G, Molinari A. Liposomes as nanomedical devices. Int J Nanomedicine. 2015;10:975.
- Gowda GAN, Zhang S, Gu H, Asiago V, Shanaiah N, Raftery D. Metabolomics-based methods for early disease diagnostics. Expert Rev Mol Diagn. 2008;8(5):617–33.
- Papanicolaou GN, Traut HF. Diagnosis of uterine cancer by the vaginal smear. New York. 1943;46.
- Mulder WJM, Strijkers GJ, Griffioen AW, van Bloois L, Molema G, Storm G, et al. A liposomal system for contrast-enhanced magnetic resonance imaging of molecular targets. Bioconjug Chem. 2004;15(4):799–806.
- Mukundan Jr S. Ghaghada KB, Badea CT, Kao CY, Hedlund LW, Provenzale JM, Johnson GA, Chen E, Bellamkonda RV, Annapragada A. A liposomal nanoscale contrast agent for preclinical CT in mice. AJR Am J Roentgenol. 2006;186(2):300–7.
- Costabile RA, Choyke PL, Frank JA, Girton ME, Diggs R, Billups KL, et al. Dynamic enhanced magnetic resonance imaging of testicular perfusion in the rat. J Urol. 1993;149(5):1195–7.
- Patravale VB, Mandawgade SD. Novel cosmetic delivery systems: an application update. Int J Cosmet Sci. 2008;30(1):19–33.
- Budai L, Kaszás N, Gróf P, Lenti K, Maghami K, Antal I, et al. Liposomes for topical use: A physico-chemical comparison of vesicles prepared from egg or soy lecithin. Sci Pharm. 2013;81(4):1151–66.
- Al-Jamal W, Kostarelos K. Liposomes: from a clinically established drug delivery system to a nanoparticle platform for theranostic nanomedicine. Acc Chem Res. 2011;44(10):1094–104.
- Svenson S. Theranostics: are we there yet? Mol Pharm. 2013;10(3):848–56.
- Mukherjee A, Paul M, Mukherjee S. Recent progress in the theranostics application of nanomedicine in lung cancer. Cancers (Basel). 2019;11(5):597.
- Yin W, Kimbrough CW, Gomez-Gutierrez JG, Burns CT, Chuong P, Grizzle WE, et al. Tumor specific liposomes improve detection of pancreatic adenocarcinoma in vivo using optoacoustic tomography. J Nanobiotechnology. 2015;13(1):1–11.
- Gurka MK, Pender D, Chuong P, Fouts BL, Sobelov A, McNally MW, et al. Identification of pancreatic tumors in vivo with ligand-targeted, pH responsive mesoporous silica nanoparticles by multispectral optoacoustic tomography. J Control release. 2016;231:60–7.
- Wallace TL, Larson JL, Bazemore SA, Wilson CW, Cossum PA. The nonclinical safety evaluation of the anticancer drug ATRAGEN®(Liposomal all-trans-retinoic acid). Int J Toxicol. 2000;19(1):33–42.
- Brogden RN, Goa KL, Coukell AJ. Amphotericin-B colloidal dispersion. A review of its use against systemic fungal infections and visceral leishmaniasis. Drugs. 1998 Sep;56(3):365–83.
- Sharma M, Joshi J, Chouhan NK, Talati MN, Vaidya S, Kumar A. Liposome-A Comprehensive Approach for Researchers. In: Molecular Pharmacology. IntechOpen; 2020.
- Chhikara BS, Parang K. Development of cytarabine prodrugs and delivery systems for leukemia treatment. Expert Opin Drug Deliv. 2010;7(12):1399–414.
- Porche DJ. Liposomal doxorubicin (Doxil). J Assoc Nurses AIDS Care. 1996;7(2):55–9.
- Wang R, Billone PS, Mullett WM. Nanomedicine in action: an overview of cancer nanomedicine on the market and in clinical trials. J Nanomater. 2013;2013.
- Peravali R, Brock R, Bright E, Mills P, Petty D, Alberts J. Enhancing the Enhanced Recovery Program in Colorectal Surgery-use of extended-release epidural morphine (DepoDur®). Ann Coloproctol. 2014;30(4):186.
- Estradiol-topical--Novavax: Estrasorb. Drugs R D. 2003;4(1):49–51.
- Lea AP, Balfour JA. Virosomal hepatitis A vaccine (strain RG-SB). BioDrugs. 1997;7(3):232–48.
- Xiong Y-Q, Kupferwasser LI, Zack PM, Bayer AS. Comparative efficacies of liposomal amikacin (MiKasome) plus oxacillin versus conventional amikacin plus oxacillin in experimental endocarditis induced by Staphylococcus aureus: microbiological and echocardiographic analyses. Antimicrob Agents Chemother. 1999;43(7):1737–42.
- Dhandapani NV, Thapa A, Sandip G, Shrestha A, Shrestha N, Bhattarai RS. Liposomes as novel drug delivery system: A comprehensive review. 2013;
- Kalepu S, Nekkanti V. Insoluble drug delivery strategies: review of recent advances and business prospects. Acta Pharm Sin B. 2015;5(5):442–53.
- Johnson EM, Ojwang JO, Szekely A, Wallace TL, Warnock DW. Comparison of in vitro antifungal activities of free and liposome-encapsulated nystatin with those of four amphotericin B formulations. Antimicrob Agents Chemother. 1998;42(6):1412–6.
- Passero Jr FC, Grapsa D, Syrigos KN, Saif MW. The safety and efficacy of Onivyde (irinotecan liposome injection) for the treatment of metastatic pancreatic cancer following gemcitabine-based therapy. Expert Rev Anticancer Ther. 2016;16(7):697–703.
- Rheumatoid Arthritis, a Laconic Review to Understand Their Basic Concept and Management Process
Abstract Views :129 |
PDF Views:0
Authors
Affiliations
1 Research Scholar, Laureate Institute of Pharmacy, Kathog, Jawalamukhi, Himachal Pradesh, 176031, IN
2 Assistant Professor, Department of Pharmaceutics, Laureate Institute of Pharmacy, Kathog, Jawalamukhi, Himachal Pradesh, 176031, IN
3 Head of Department, Department of Pharmaceutics, Laureate Institute of Pharmacy, Kathog, Jawalamukhi, Himachal Pradesh, 176031, IN
4 Director cum Principal, Laureate Institute of Pharmacy, Kathog, Jawalamukhi, Himachal Pradesh 176031, IN
5 Assistant Professor, Laureate Institute of Pharmacy, Jawalmukhi - 176031, Himachal Pradesh, IN
1 Research Scholar, Laureate Institute of Pharmacy, Kathog, Jawalamukhi, Himachal Pradesh, 176031, IN
2 Assistant Professor, Department of Pharmaceutics, Laureate Institute of Pharmacy, Kathog, Jawalamukhi, Himachal Pradesh, 176031, IN
3 Head of Department, Department of Pharmaceutics, Laureate Institute of Pharmacy, Kathog, Jawalamukhi, Himachal Pradesh, 176031, IN
4 Director cum Principal, Laureate Institute of Pharmacy, Kathog, Jawalamukhi, Himachal Pradesh 176031, IN
5 Assistant Professor, Laureate Institute of Pharmacy, Jawalmukhi - 176031, Himachal Pradesh, IN
Source
Asian Journal of Pharmaceutical Research, Vol 12, No 4 (2022), Pagination: 312 - 322Abstract
Rheumatoid arthritis is a chronic inflammatory illness characterized by joint stiffness, bone and cartilage destruction, and swelling above the joints. The condition is linked to chemicals found within the major histocompatibility complex, also as T-cells that are hooked in to them. The condition is more severe in women than in men, also as within the elderly population. The effects of gender on the clinical course of the disease are studied, but the results are mixed. The factor like genetic, environmental, smoking, and age of a person were trigger’s the rheumatoid arthritis. The other clinical complications were observed in patients with rheumatoid arthritis which includes depression, infection, malignancy, cardiovascular disorder, pulmonary disease etc. According to research, RA risk might be impacted by a genetic predisposition, environmental factors, or a combination of both. Immune cells such as lymphocytes, neutrophils, and macrophages have long been thought to have a role in the development of RA involved in pathological mechanism. Rheumatoid arthritis have been diagnosed by imaging with colour doppler sonography or gadolinium-enhanced magnetic resonance imaging can detect the presence of osynovitis, and serologic testing for auto-antibodies and APRs was required to diagnose rheumatoid arthritis. To cure and prevent the patients form rheumatoid arthritis it is very necessary to take suitable treatment. So, in present work we also highlighted the available drugs used for the treatment of RA. The first line therapy agents include Non-steroidalantiinflammatory drugs, and corticosteroids. The second line agents used in RA are Disease modifying Antirheumatic drugs (DMARDs). The patients having age more than 60 years also need surgery to cure rheumatoid arthritis. To decrease the side effects from some potent agents include methotrexate the vitamin D, folic acid, and dietary supplements were used with treatment. So, this review article helps the researcher’s to understand the basic overview of rheumatoid arthritis, causes, other disease development, and management process with regards to available FDA approved therapeutics, and published patents.
Keywords
Rheumatoid arthritis, Etiology, Pathophysiology, Diagnosis, TreatmentReferences
- Aloke C, Ibiam UA, Orji OU, Ugwuja EI, Ezeani NN, Aja PM, Obasi NA. Anti-arthritic potentials of ethanol and aqueous extracts of stem bark of Cleistopholis patens on complete Freund's adjuvant-induced rheumatoid arthritis in rats. Journal of Ayurveda and Integrative Medicine. 2019:9.
- 2. Girdler SJ, Ye I, Tang R, Kirschner N. Altering the natural history of rheumatoid arthritis: The role of Immunotherapy and biologics in orthopaedic care. Journal of Orthopaedics. 2020; 17:17-21.
- Esposito AJ, Chu SG, Madan R, Doyle TJ, Dellaripa PF. Thoracic manifestations of rheumatoid arthritis. Clinics in Chest Medicine. 2019;40(3):545-60.
- Jayashree S, Nirekshana K, Guha G, Bhakta-Guha D. Cancer chemotherapeutics in rheumatoid arthritis: A convoluted connection. Biomedicine and Pharmacotherapy. 2018; 102:894-911.
- Arjun Patidar, S.C.Shivhare, Umesh Ateneriya, Sonu Choudhary. A Comprehensive Review on Breast Cancer. Asian J. Nur. Edu. and Research 2(1): Jan.-March 2012; Page 28-32.
- Tanaka S. Emerging anti-osteoclast therapy for rheumatoid arthritis. Journal of Orthopaedic Science. 2018;23(5):717-21.
- Wang X, Fang G, Yang Y, Pang Y. The newly discovered natural compounds against rheumatoid arthritis-an overview. Phytochemistry Letters. 2019; 34:50-8.
- Rekha Rani Nar, Ashok Kumar, S. Jeeva. Assessment and comparison of knowledge and attitude regarding pulmonary tuberculosis and compliance to Anti-Tuberculosis Treatment (A TT) of pulmonary tuberculosis patients under intensive and continuation phase of treatment at selected DOTS centers of Ambala, Haryana. Asian J. Nur. Edu. and Research 2(4): Oct-Dec. 2012; Page 190-194.
- Martins P, Fonseca JE. How to investigate: Pre-clinical rheumatoid arthritis. Best Practice and Research Clinical Rheumatology. 2019;33(4):101438.
- Alpízar-Rodríguez D, Pluchino N, Canny G, Gabay C, Finckh A. The role of female hormonal factors in the development of rheumatoid arthritis. Rheumatology. 2017;56(8):1254-63.
- Ramachandra. Hypochondria - Historical Perspectives, Diagnosis and Management. Asian J. Nur. Edu. and Research 3(4): Oct.- Dec., 2013; Page 219-223.
- ChangK,YangSM,KimSH,HanKH,ParkSJ,ShinJI.Smokingand rheumatoid arthritis. International Journal of Molecular Sciences. 2014;15(12):22279-95.
- Margaretten M, Julian L, Katz P, Yelin E. Depression in patients with rheumatoid arthritis: description, causes and mechanisms. International Journal of Clinical Rheumatology. 2011;6(6):617.
- Atzeni F, Masala IF, Di Franco M, Sarzi-Puttini P. Infections in rheumatoid arthritis. Current Opinion in Rheumatology. 2017;29(4):323-30.
- Neethu Jose. Bee Venom Therapy (BVT). Asian J. Nur. Edu. and Research 5(2): April-June 2015; Page 293-296.
- Ellman P, Ball RE. “Rheumatoid disease” with joint and pulmonary manifestations. British Medical Journal. 1948;2(4583):816.
- Esposito AJ, Chu SG, Madan R, Doyle TJ, Dellaripa PF. Thoracic manifestations of rheumatoid arthritis. Clinics in Chest Medicine. 2019;40(3):545-60.
- Choy E, Ganeshalingam K, Semb AG, Szekanecz Z, Nurmohamed M. Cardiovascular risk in rheumatoid arthritis: recent advances in the understanding of the pivotal role of inflammation, risk predictors and the impact of treatment. Rheumatology. 2014;53(12):2143-54.
- Nirmala Jyothi. A Case Report on Pica: A rare pregnancy related complication. Asian J. Nur. Edu. and Research 5(1): Jan.-March 2015; Page137-139.
- Wegierska M, Dura M, Blumfield E, Żuchowski P, Waszczak M, Jeka S. Osteoporosis diagnostics in patients with rheumatoid arthritis. Reumatologia. 2016;54(1):29.
- Huber LC, Distler O, Tarner I, Gay RE, Gay S, Pap T. Synovial fibroblasts: key players in rheumatoid arthritis. Rheumatology. 2006;45(6):669-75.
- Choy E. Understanding the dynamics: pathways involved in the pathogenesis of rheumatoid arthritis. Rheumatology. 2012;51(suppl_5): v3-11.
- Byng-Maddick R, Ehrenstein MR. The impact of biological therapy on regulatory T cells in rheumatoid arthritis. Rheumatology. 2015;54(5):768-75.
- Jophin Joseph. Pierre Robin Sequence / Pierre Robin malformation. Asian J. Nur. Edu. and Research. 2016; 6(2): 265-273.
- Tran CN, Lundy SK, Fox DA. Synovial biology and T cells in rheumatoid arthritis. Pathophysiology. 2005;12(3):183-9.
- Bugatti S, Vitolo B, Caporali R, Montecucco C, Manzo A. B cells in rheumatoid arthritis: from pathogenic players to disease biomarkers. BioMed Research International. 2014.
- Kekow J, Koczan D, Drynda S, Drynda A, Thiesen H. Modulation of the gene expression pattern in peripheral blood mononuclear cells by biologicals in rheumatoid arthritis. Arthritis Res Ther. 2003;5(3):1-54.
- Boissier MC, Semerano L, Challal S, Saidenberg-Kermanac'h N, Falgarone G. Rheumatoid arthritis: from autoimmunity to synovitis and joint destruction. Journal of Autoimmunity. 2012;39(3):222-8.
- Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, Birnbaum NS, Burmester GR, Bykerk VP, Cohen MD, Combe B. American College of Rheumatology, European League Against Rheumatism, et al: Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010; 62:2569-81.
- Radner H, Neogi T, Smolen JS, Aletaha D. Performance of the 2010 ACR/EULAR classification criteria for rheumatoid arthritis: a systematic literature review. Annals of the Rheumatic Diseases. 2014;73(1):114-23.
- Aggarwal R, Ringold S, Khanna D, Neogi T, Johnson SR, Miller A, Brunner HI, Ogawa R, Felson D, Ogdie A, Aletaha D. Distinctions between diagnostic and classification criteria?. Arthritis Care and Research. 2015;67(7):891.
- Mohd. Yaqub Khan, Poonam Gupta, Vikas Kumar Verma. A Review- Biomedical Engineering-Present and Future Prospective.Asian J. Pharm. Res. 3(4): Oct. - Dec.2013; Page 202-206.
- Emery P, Breedveld FC, Dougados M, Kalden JR, Schiff MH, Smolen JS. Early referral recommendation for newly diagnosed rheumatoid arthritis: evidence based development of a clinical guide. Annals of the Rheumatic Diseases. 2002;61(4):290-7.
- Aletaha D, Nell VP, Stamm T, Uffmann M, Pflugbeil S, Machold K, Smolen JS. Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. Arthritis Research and Therapy. 2005;7(4):1-1.
- Van der Heijde DM, van Riel PL, van Leeuwen MA. vant Hof MA, van Rijswijk MH, van de Putte LB. Prognostic factors for radiographic damage and physical disability in early rheumatoid arthritis. Br J Rheumatol. 1992; 8:519-26.
- St Clair EW. Active-Controlled Study of Patients Receiving Infliximab for the Treatment of Rheumatoid Arthritis of Early Onset Study Group. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: randomized, controlled trial. Arthritis Rheum. 2004; 50:3432-43.
- Smolen JS, Breedveld FC, Burmester GR, Bykerk V, Dougados M, Emery P, Kvien TK, Navarro-Compán MV, Oliver S, Schoels M, Scholte-Voshaar M. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Annals of the Rheumatic Diseases. 2016;75(1):3-15.
- Studenic P, Smolen JS, Aletaha D. Near misses of ACR/EULAR criteria for remission: effects of patient global assessment in Boolean and index-based definitions. Annals of the Rheumatic Diseases. 2012;71(10):1702-5.
- Felson DT, Smolen JS, Wells G, Zhang B, Van Tuyl LH, Funovits J, Aletaha D, Allaart CF, Bathon J, Bombardieri S, Brooks P. American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis and Rheumatism. 2011;63(3):573-86.
- Bullock J, Rizvi SA, Saleh AM, Ahmed SS, Do DP, Ansari RA, Ahmed J. Rheumatoid arthritis: a brief overview of the treatment. Medical Principles and Practice. 2018;27(6):501-7.
- Krushna K. Zambare, Avinash B. Thalkari. Overview on Pathophysiology of Pneumonia. Asian J. Pharm. Res. 2019; 9(3):177-180.
- Combe B, Landewe R, Daien CI, Hua C, Aletaha D, Álvaro-Gracia JM, Bakkers M, Brodin N, Burmester GR, Codreanu C, Conway R. 2016 update of the EULAR recommendations for the management of early arthritis. Annals of the Rheumatic Diseases. 2017;76(6):948-59.
- Liu D, Ahmet A, Ward L, Krishnamoorthy P, Mandelcorn ED, Leigh R, Brown JP, Cohen A, Kim H. A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy. Allergy, Asthma and Clinical Immunology. 2013;9(1):1-25.
- Smolen JS, Landewé R, Breedveld FC, Dougados M, Emery P, Gaujoux-Viala C, Gorter S, Knevel R, Nam J, Schoels M, Aletaha D. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Annals of the Rheumatic Diseases. 2010;69(6):964-75.
- Combe B, Landewe R, Daien CI, Hua C, Aletaha D, Álvaro-Gracia JM, Bakkers M, Brodin N, Burmester GR, Codreanu C, Conway R. 2016 update of the EULAR recommendations for the management of early arthritis. Annals of the Rheumatic Diseases. 2017;76(6):948-59.
- Silva JC, Mariz HA, Rocha LF, Oliveira PS, Dantas AT, Duarte AL, Pitta ID, Galdino SL, Pitta MG. Hydroxychloroquine decreases Th17- related cytokines in systemic lupus erythematosus and rheumatoid arthritis patients. Clinics. 2013; 68:766-71.
- Volin MV, Harlow LA, Woods JM, Campbell PL, Amin MA, Tokuhira M, Koch AE. Treatment with sulfasalazine or sulfapyridine, but not 5‐aminosalicylic acid, inhibits basic fibroblast growth factor–induced endothelial cell chemotaxis. Arthritis and Rheumatism: Official Journal of the American College of Rheumatology. 1999;42(9):1927-35.
- Kanchan R Pagar, Sarika V Khandbahale, Poonam M Kasar. Osteoarthritis: Pathophysiology and Current Treatment Modalities. Asian J. Pharm. Res. 2019; 9(4):289-298.
- Kumar P, Banik S. Pharmacotherapy options in rheumatoid arthritis. Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders. 2013;6: CMAMD-S5558.
- Bullock J, Rizvi SA, Saleh AM, Ahmed SS, Do DP, Ansari RA, Ahmed J. Rheumatoid arthritis: a brief overview of the treatment. Medical Principles and Practice. 2018;27(6):501-7.
- Rein P, Mueller RB. Treatment with biologicals in rheumatoid arthritis: an overview. Rheumatology and Therapy. 2017;4(2):247-61.
- Tovey MG, Lallemand C. Immunogenicity and other problems associated with the use of biopharmaceuticals. Therapeutic Advances in Drug Safety. 2011;2(3):113-28.
- Halstead JA, Stoten S. Orthopedic Nursing: Caring for Patients with Musculoskeletal Disorders. Bridgewater: Western Schools. 2010.
- Kanchan R Pagar, Sarika V Khandbahale, Poonam M Kasar. Osteoarthritis: Pathophysiology and Current Treatment Modalities. Asian J. Pharm. Res. 2019; 9(4):289-298.
- Bullock J, Rizvi SA, Saleh AM, Ahmed SS, Do DP, Ansari RA, Ahmed J. Rheumatoid arthritis: a brief overview of the treatment. Medical Principles and Practice. 2018;27(6):501-7.
- Cooney JK, Law RJ, Matschke V, Lemmey AB, Moore JP, Ahmad Y, Jones JG, Maddison P, Thom JM. Benefits of exercise in rheumatoid arthritis. Journal of Aging Research.13;2011
- Zitnay JL, Li Y, Qin Z, San BH, Depalle B, Reese SP, Buehler MJ, Yu SM, Weiss JA. Molecular level detection and localization of mechanical damage in collagen enabled by collagen hybridizing peptides. Nature Communications. 2017;8(1):1-2.
- Burska AN, Roget K, Blits M, Gomez LS, Van De Loo F, Hazelwood LD, Verweij CL, Rowe A, Goulielmos GN, Van Baarsen LG, Ponchel F. Gene expression analysis in RA: towards personalized medicine. The Pharmacogenomics Journal. 2014;14(2):93-106.
- Nakamura S, Suzuki K, Iijima H, Hata Y, Lim CR, Ishizawa Y, Kameda H, Amano K, Matsubara K, Matoba R, Takeuchi T. Identification of baseline gene expression signatures predicting therapeutic responses to three biologic agents in rheumatoid arthritis: a retrospective observational study. Arthritis Research and Therapy. 2016;18(1):1-2.
- Gonzalez-Alvaro I, Ortiz AM, Seoane IV, Garcia-Vicuna R, Martínez C, Gomáriz RP. Biomarkers predicting a need for intensive treatment in patients with early arthritis. Current Pharmaceutical Design. 2015;21(2):170-81.
- Feldman M, Maini RN, Williams RO, inventors; Kennedy Mathilda, Terence Institute of Rheumatology Trust, assignee. Treatment of rheumatoid arthritis with anti-CD4 antibodies in conjunction with anti- TNF antibodies. United States Patent US 5,741,488. 1998 Apr 21.
- Dennis G, Martin F, Townsend MJ, inventors; Genentech Inc, assignee. Methods for treating, diagnosing, and monitoring rheumatoid arthritis. United States Patent US 8,728,730. 2014 May 20.
- Cavet GL, Shen Y, Knowlton N, Centola M, inventors; Oklahoma Medical Research Foundation, Crescendo Bioscience Inc, assignee. Biomarkers and methods for measuring and monitoring inflammatory disease activity. United States Patent US 9,200,324. 2015 Dec 1.
- Stolle RJ, Beck LR, inventors; Stolle Research, Development Corp, assignee. Prevention and treatment of rheumatoid arthritis. United States Patent US 4,732,757. 1988 Mar 22.
- Nithyashree RS, Deveswaran R. A Comprehensive Review on Rheumatoid Arthritis. Journal of Pharmaceutical Research International. 2020 Jul 27:18-32.
- Spencer WP, Millsap PS. Esterified fatty acid composition - IMAGENETIX, INC. Freepatentsonline.com; 2009. [Online] Available:http://www.freepatentsonline.com /y2009/0252692.html (Accessed 17 December 2019)
- Tetracycline Compounds for the Treatment of Rheumatoid Arthritis and Related Methods of Treatment - Patent US2010190755 - PubChem. Available:https://pubchem.ncbi.nlm.nih.gov /patent/US2010190755 (Accessed: 21 December 2019)
- Google.com. WO2015177097A1 - Treatment for rheumatoid arthritis - Google Patents; 2015. [Online] Available:https://patents.google.com/paten t/WO2015177097A1/en (Accessed 17 December 2019)
- Freepatentsonline.com. FPO IP Research and Communities; 2019. [Online] Available: http://www.freepatentsonline.com/result.html?sort=relevance&srch=to p&query_txt=5908628&submit=&patents_us=o n (Accessed 17 December 2019)
- Golini JM. Cetylated fatty acid and alkali buffered creatine anti- inflammatory composition –Golin, JeffreyM. Freepatentsonline.com; 2011. [Online] Available:http://www.freepatentsonline.co m/y2011/0039928.html (Accessed 17 December 2019)
- Cohen R, Belder-Carr S, Hagerty D, Peach RJ, Becker JC, inventors; Bristol Myers Squibb Co, assignee. Methods for treating juvenile rheumatoid arthritis by administering a soluble CTLA4 molecule. United States patent US 8,703,718. 2014 Apr 22.
- Dennis G, Martin F, Townsend MJ, inventors; Genentech Inc, assignee. Methods for treating, diagnosing, and monitoring rheumatoid arthritis. United States Patent US 8,728,730. 2014 May 20.
- LingNC,WangSL,WangD,SinghS,inventors;NestecSA,assignee. Citrullinated peptides for diagnosing and prognosing rheumatoid arthritis. United States Patent US 8,519,096. 2013 Aug 27.
- Thompson P, Blumberg H, Chandrasekher YA, Novak JE, inventors; Zymogenetics Inc, assignee. Method of treating rheumatoid arthritis using anti-IL-20 antibodies. United States Patent US 8,728,469. 2014 May 20.
- Trentham DE, Weiner HL, Hafler DA, inventors; Autoimmune Inc, assignee. Method of treating rheumatoid arthritis with type II collagen. United States Patent US 5,399,347. 1995 Mar 21.
- Feldman M, Maini RN, Williams RO, inventors; Kennedy Mathilda, Terence Institute of Rheumatology Trust, assignee. Treatment of rheumatoid arthritis with anti-CD4 antibodies in conjunction with anti- TNF antibodies. United States Patent US 5,741,488. 1998 Apr 21.
- Van'tklooster GA, Namour FS, Brys RC, Van Rompaey LJ, inventors; Galapagos NV , assignee. Aminotriazolopyridine for use in the treatment of inflammation, and pharmaceutical compositions thereof. United States Patent US 9,284,311. 2016 Mar 15.
- O'brien PM, Anderson E, Bolton GL, Ferguson DA, Jiang X, Kral Jr RM, Visnick M, inventors; Reata Pharmaceuticals Inc, assignee. Compounds Including an Anti-inflammatory Pharmacore and Methods of use. 2015 Jan 21.
- Menet CJ, Hodges AJ, Vater HD, inventors; Galapagos NV, assignee. Compound useful for the treatment of degenerative and inflammatory diseases. United States Patent US 8,802,682. 2014 Aug 12.
- Medich JR, Ruperto N, Martini A, Lovell DJ, Giannini EH, inventors; AbbVie Biotechnology Ltd, assignee. Uses and Compositions for Treatment of Juvenile Rheumatoid Arthritis. United States Patent application US 14/935,991. 2016 Sep 29.
- Huang X, Jasson M, Marks V, Radin A, Fan C, Van Hoogstraten H, Fiore S, Van Adelsberg J, Genovese M, inventors; Sanofi Biotechnology SAS, Regeneron Pharmaceuticals Inc, assignee. Compositions for the treatment of rheumatoid arthritis and methods of using same. United States Patent Application US 15/034,531. 2016 Sep 29.
- Palombella VJ, Kutok JL, inventors; Infinity Pharmaceuticals Inc, assignee. Treatment of rheumatoid arthritis and asthma using pi3 kinase inhibitors. United States Patent Application US 13/839,912. 2014 May 1.
- Vakkalanka SK, Viswanadha S, inventors; Rhizen Pharmaceuticals SA, assignee. Pharmaceutical compositions containing a PDE4 inhibitor and a PI3 delta or dual PI3 delta-gamma kinase inhibitor. United States Patent US 9,737,521. 2017 Aug 22.
- Fisher E, Edwards III C, Kieft G, inventors; Amgen Inc, assignee. Nucleic acids encoding truncated soluble tumor necrosis factor. United States Patent US 7,732,587. 2010 Jun 8.
- Menet CJ, Hodges AJ, Vater HD, inventors; Galapagos NV, assignee. Compound useful for the treatment of degenerative and inflammatory diseases. United States Patent US 8,802,682. 2014 Aug 12.
- Schwaeble HW, Dudler T, Tedford CE, Parent JB, Demopulos GA, inventors; University of Leicester, Omeros Medical Systems Inc, assignee. Methods for treating disseminated intravascular coagulation by inhibiting MASP-2 dependent complement activation. United States Patent US 8,652,477. 2014 Feb 18.
- Kesharwani D, Paliwal R, Satapathy T, Paul SD. Rheumatiod arthritis: An updated overview of latest therapy and drug delivery. Journal of Pharmacopuncture. 2019;22(4):210.
- A Detailed Review on Fast Dissolving Niosomal Films for Sublingual Drug Delivery
Abstract Views :109 |
PDF Views:0
Authors
Affiliations
1 Department of Pharmaceutics, Laureate Institute of Pharmacy, Kathog, Jawalamukhi, Kangra (H.P.) 177101,, IN
1 Department of Pharmaceutics, Laureate Institute of Pharmacy, Kathog, Jawalamukhi, Kangra (H.P.) 177101,, IN
Source
Research Journal of Pharmaceutical Dosage Form and Technology, Vol 14, No 2 (2022), Pagination: 163-170Abstract
Fast dissolving or Quick-dissolving dosage forms have great importance in the pharmaceutical field due to their special properties and advantages. Fast-dissolving dosage forms breakdown immediately in the salivary fluids of the oral cavity within a minute, where they release the active pharmaceutical ingredient. Sublingual drug delivery system is a novel route of drug administration in which the drug substance is placed under the tongue and is directly absorbed via the blood vessels and produces the immediate onset of action. Noisome are closed bilayer vesicles formed by self-assembly of nonionic surfactant in an aqueous medium. Noisome is similar to liposome but has the ability to increase the stability of the drug. Formulated niosomes are added into the film forming polymers to obtain sublingual niosomal films. Fast dissolving niosomal film is suitable for the drugs which show high first-pass metabolism or hepatic metabolism, low bioavailability drugs, and have a short half life drugs. Fast Dissolving Niosomal Films used to improve the oral bioavailability and reduce the dose and dosing frequency, which reduce systemic side effects and as well as cost-effective. Niosomes allow the prolonged release of the drug and film was used to increase the bioavailability of drugs via the sublingual route of drug administration. Fast dissolving niosomal films have great importance during emergency conditions like allergy, short-term spasm, and asthma whenever an immediate onset of action is required. Fast dissolving films are also suitable for pediatric, geriatric, and dysphasic patients or patients with fear of choking.Keywords
Fast-dissolving drug–delivery, Geriatric, Solvent casting, Pediatric, Bioavailability.References
- Siddiqui, MD Nehal, Garima Garg, and Pramod Kumar Sharma. "A Short Review on “A Novel Approach in Oral Fast Dissolving Drug Delivery System and Their Patents”." Advances in Biological Research 5.6 (2011): 291-303.
- Allam A, Fetih G. Sublingual fast dissolving niosomal films for enhanced bioavailability and prolonged effect of metoprolol tartrate. Drug Des Devel Ther. 2016 Aug 2;10: 2421-33. doi: 10.2147/DDDT.S113775. PMID: 27536063; PMCID: PMC4977085.
- Auda SH, Fathalla D, Fetih G, El-Badry M, Shakeel F. Niosomes as transdermal drug delivery system for celecoxib: in vitro and in vivo studies. Polymer Bulletin. 2016 May 1;73(5):1229-45. DOI 10.1007/s00289-015-1544-8
- Frey P. Film strips and pharmaceuticals. Pharma. Mfg. & Packag. Sourcer. 2006:92-3.
- Chien YW. Novel drug delivery systems. Drugs and the pharmaceutical sciences. 1992;50.
- El-Badry M, Fetih G, Fathalla D, Shakeel F. Transdermal delivery of meloxicam using niosomal hydrogels: in vitro and pharmacodynamic evaluation. Pharm Dev Technol. 2015 Nov;20(7):820-826. doi: 10.3109/10837450.2014.926919. Epub 2014 Jun 9. PMID: 24909736.
- Naimish AS, Vipul PP, Devang JP. Sublingual Delivery: A Promising approach to improve Bioavailability. Pharma Science Monitor. 2013 Apr 1;4(2). ISSN: 0976-7908
- Thakur N, Bansal M, Sharma N, Yadav G, Khare P. Overview “a novel approach of fast dissolving films and their patients”. Advances in Biological Research. 2013;7(2):50-8. DOI: 10.5829/idosi.abr.2013.7.2.72134
- Sharma, D., Kaur, D., Verma, S., Singh, D., Singh, M., Singh, G., & Garg, R. (2015). Fast dissolving oral films technology: A recent trend for an innovative oral drug delivery system. International Journal of Drug Delivery, 7(2), 60-75. Retrieved from http://www.arjournals.org/index.php/ijdd/article/view/ 1692
- Arya A, Chandra A, Sharma V, Pathak K. Fast dissolving oral films: an innovative drug delivery system and dosage form. International Journal of ChemTech Research. 2010 Jan; 2(1):576- 83.
- Juluru NS. Fast dissolving oral films: A review. IJAPBC. 2013 Jan;2(1):108-12.
- Allam A, Fetih G. Sublingual fast dissolving niosomal films for enhanced bioavailability and prolonged effect of metoprolol tartrate. Drug Des Devel Ther. 2016 Aug 2;10:2421-33. doi: 10.2147/DDDT.S113775. PMID: 27536063; PMCID: PMC4977085.
- Pathan A, Gupta MK, Dubey A, Agrawal A, Jain NK. Fast dissolving oral films: A review. Current Res. in Bio & Pharm Sci. 2015; 4(5):19-26. ISSN: 2349-7750
- Nagar, P. & Chauhan, Iti & Yasir, Mohd. (2011). Insights into polymers: Film formers in mouth dissolving films. Drug Invention Today. 3. 280-289.
- Dixit RP, Puthli SP. Oral strip technology: overview and future potential. J Control Release. 2009 Oct 15;139(2):94-107. doi: 10.1016/j.jconrel.2009.06.014. Epub 2009 Jun 24. PMID: 19559740.
- Mennella JA, Beauchamp GK. Optimizing oral medications for children. Clin Ther. 2008 Nov;30(11):2120-32. doi: 10.1016/j.clinthera.2008.11.018. PMID: 19108800; PMCID: PMC2744307.
- McGregor, R., Homan, H., & Gravina, S. (2004). Fast dissolving film delivery of nucleotides that inhibit the unpleasant taste of bitter tasting medications. WO Patent, 19885.
- Rawat, Shilpi, D. V. Derle, Sulbha R. Fukte, Pramod R. Shinde, and Balasaheb S. Parve. "Superdisintegrants: an overview." World journal of pharmacy and pharmaceutical sciences 3, no. 5 (2014): 263-278.
- Ravi Kumar K, Mercy Sulochana M. Fast dissolving films: a unique strategy for drug delivery. Asian J. Pharm. Res. 2014;4(1):47-55. Ravi Kumar K, Mercy Sulochana M. Fast dissolving films: a unique strategy for drug delivery. Asian J. Pharm. Res. 2014;4(1):47-55.
- Patil, S. L., Mahaparale, P. R., Shivnikar, M. A., Tiwari, S. S., Pawar, K. V., & Sane, P. N. (2012). Fast dissolving oral films: An innovative drug delivery system. International journal of Research and Reviews in Pharmacy and Applied science, 2(3), 482-496. ISSN NO. 2271-3681
- Pechová V, Gajdziok J, Muselík J, Vetchý D. Development of Orodispersible Films Containing Benzydamine Hydrochloride Using a Modified Solvent Casting Method. AAPS PharmSciTech. 2018 Aug;19(6):2509-2518. doi: 10.1208/s12249-018-1088-y. Epub 2018 Jun 11. PMID: 29948980.
- Bhyan, Bhupinder & Jangra, S. & Kaur, M. & Singh, H. (2011). Orally fast dissolving films: Innovations in formulation and technology. International Journal of Pharmaceutical Sciences Review and Research. 9. 50-57.
- Lade, M. S., S. A. Payghan, Z. J. Tamboli, and J. I. Disouza. "Polymer based wafer technology: A Review." International Journal of Pharmaceutical and Biological Archives 4, no. 6 (2013): 1060-1074.
- Panda, Bibhu Prasad, N. S. Dey, and M. E. B. Rao. "Development of innovative orally fast disintegrating film dosage forms: a review." International Journal of Pharmaceutical Sciences and Nanotechnology 5, no. 2 (2012): 1666-1674.
- Bala R, Pawar P, Khanna S, Arora S. Orally dissolving strips: A new approach to oral drug delivery system. Int J Pharm Investig. 2013;3(2):67-76. doi:10.4103/2230-973X.114897
- Patel D, Patel M, Upadhyay P, Shah N, Shah S. A Review on Mouth Dissolving Film. J Pharm. Sci. and Bioscientific Res. 2015; 5(3): 266-273. ISSN NO. 2271-3681
- Rathi, Varun, V. Senthil, Lavanya Kammili, and Ritu Hans. "A Brief review on oral film Technology." International Journal of Research in Ayurveda and Pharmacy 2, no. 4 (2011).
- Jyoti, A., Gurpreet, S., Seema, S. and Rana, A.C., 2011. Fast dissolving films: A novel approach to oral drug delivery. International research journal of pharmacy, 2(12), pp.69-74.
- Nagendrakumar, D., Keshavshetti GG, Pratibha Mogale, Swati Swami, and Harshanand Swami. "Formulation and evaluation of fast dissolving oral films of metoprolol sccinate." International Journal of Engineering 6, no. 4 (2015): 8269.
- Gowri, R., N. Narayanan, S. Revathy, P. Prabhavathy, G. Preethy Mol, and G. Rekha. "Melt in mouth films-an effective alternative drug delivery system." Int J Bio and Pharm Res 4, no. 9 (2013): 645-650.
- Karthikeyan, D., Sanju Sri, and C. Santhosh Kumar. "Development of fast dissolving oral film containing of rizatriptan benzoate as an antimigraine medication." Indo American Journal of Pharmaceutical Research 3, no. 3 (2013): 2642-2654.
- Felton, Linda A., Patrick B. O’Donnell, and James W. McGinity. "Mechanical properties of polymeric films prepared from aqueous dispersions." In Aqueous polymeric coatings for pharmaceutical dosage forms, pp. 125-148. CRC Press, 2008.
- Fulzele, S. V., Satturwar, P. M., andDorle, A. K. (2002). Polymerized rosin: novel film forming polymer for drug delivery. International journal of pharmaceutics, 249(1-2), 175-184. https://doi.org/10.1016/S0378-5173(02)00529-X
- Patel, R. S., and Poddar, S. S. (2009). Development and characterization of mucoadhesive buccal patches of salbutamol sulphate. Current drug delivery, 6(1), 140-144. DOI: https://doi.org/10.2174/156720109787048177
- Patel D, Patel M, Upadhyay P, Shah N, Shah S. A Review on Mouth Dissolving Film. J Pharm. Sci. and Bioscientific Res. 2015; 5(3): 266-273.
- Nair, Sreeja C., and K. R. Anoop. "Design and in vitro evaluation of controlled release satranidazole subgingival films for periodontitis therapy." Int J Pharm Sci Rev Res 24, no. 1 (2014): 8-14.
- Bala R, Pawar P, Khanna S, Arora S. Orally dissolving strips: A new approach to oral drug delivery system. Int J Pharm Investig. 2013 Apr;3(2):67-76. doi: 10.4103/2230-973X.114897. PMID: 24015378; PMCID: PMC3757902.
- D. Archana J, Vijaya V, Dr. Uma MR, Formulation and evaluation of oral thin films containing saxagliptin, IJJIPSR, 2, 2014, 2669- 2690.
- Peppas, Nikolaos and Buri, Pierre. (1985). Surface, interfacial and molecular aspects of polymer bioadhesion on soft tissues. Journal of Controlled Release. 2. 257-275. 10.1016/0168-3659(85)90050- 1.
- Meathrel, B., and Moritz, C. A. T. H. Y. (2007). Dissolvable films and their potential in IVDs. IVD Technol, 13(9), 53-58.
- Dixit RP, Puthli SP. Oral strip technology: overview and future potential. J Control Release. 2009 Oct 15;139(2):94-107. doi: 10.1016/j.jconrel.2009.06.014. Epub 2009 Jun 24. PMID: 19559740.
- Vishwkarma, D. and Tripathi, A. and Yogesh, P. and Maddheshiyab, B. (2011). Review article on mouth dissolving film. J Glob Pharm Technol. 3. 10.1234/jgpt.v3i1.335.
- Application of Berberine on Skin Diseases: A Review
Abstract Views :349 |
PDF Views:0
Authors
Keshav Dhiman
1,
Anshul Sharma
1,
Anshul Sharma
1,
Kamya Goyal
2,
Vinay Pandit
1,
M. S. Ashawat
1,
Shammy Jindal
1
Affiliations
1 Department of Pharmaceutics, Laureate Institute of Pharmacy, Kathog Jawalaji Dist - Kangra (H.P.), IN
2 Department of Pharmaceutical Analysis and Quality Assurance, Laureate Institute of Pharmacy, Kathog Jawalaji Dist - Kangra (H.P.), IN
1 Department of Pharmaceutics, Laureate Institute of Pharmacy, Kathog Jawalaji Dist - Kangra (H.P.), IN
2 Department of Pharmaceutical Analysis and Quality Assurance, Laureate Institute of Pharmacy, Kathog Jawalaji Dist - Kangra (H.P.), IN
Source
Research Journal of Pharmaceutical Dosage Form and Technology, Vol 14, No 4 (2022), Pagination: 304-308Abstract
The plants containing berberine have been used for the treatment of skin diseases, inflammatory disorders, and reducing fevers, wound healing, digestive and respiratory diseases and in treatment of tumors. By taking the specific properties of the berberine, this review describes the method mentioned in the literature regarding the berberine extraction. Furthermore, many experimental and clinical studies suggest that berberine has several pharmacological activities such as antioxidative, cardioprotective, nephroprotective, and hepatoprotective effect. This review summarizes the information about botanical occurrence, traditional uses and pharmacological effects of berberine and berberine containing plants.Keywords
Berberine, Skin Diseases, Psoriasis.References
- Chen Y Y, Chang F R, Wu Y C. Isoquinoline alkaloids and lignans from Rollinia mucosa. Journal of Natural Products. 1996; 59: 904-906.
- Singh A, Duggal S, Kaur N, Singh J. Berberine: Alkaloid with wide spectrum of pharmacological activities. J. Nat. Prod.2010; 3: 64–75.
- Dev S. A Selection of Prime Ayurvedic Plants Drugs ancientModern Concordance. New Delhi: Anamaya Publishers; 2006.
- Kirtikar K R, Basu B D. Indian Medicinal Plants. Allahabad : CSIR Publications. 1998;1.
- Kataoka M, Tokuyama E, Miyananga Y, Uchida T. The taste sensory evaluation of medicinal plants and Chinese medicines. Int. J. Pharm. 2008; 36–44.
- Fabricant D S, Famsworth N R. The value of plants used in traditional medicine for drug discovery. Journal of Environmental Health Perspectives. 2005; 69.
- Rosjanga P, Gritsanapan W. Variation of berberine content in the Coscinium fenestratum Stem in Thailand Market. Mahidol University Journal of Pharmaceutical Sciences. 2005;32: 66-70
- Andola H C, Gaira K S, Rawal M S, Bhatt I D, Purohit V K. Variations of berberine content of Berberis asiatica. Western Himalaya Chem Biodiversity. (2010a) ; 7:415-420.
- Andola H C, Rawal R S, Rawat M S M, Bhatti I D, Purohit V K. Variations of berberine contents in Berberis pseudumbellata. A High Value Medicinal shrub of West Himalaya. India Medicinal plants Journal of Phytomedicines and related industries. (2010b); 2: 111-115.
- Tome F, Colombo M L. Distribution of alkaloids in Chelidonium majus and factor affecting their accumulation. Phytochemistry. 1995; 37-39.
- Chandra P, Purohit A N. Berberine contents and alkaloid profile of Berberis species from different altitudes. Biochemistry systems Ecology. 1980; 379-380.
- Mikage M, Mouri C. Pharmacognostical studies of Berberis plants from Nepal (1) altitudinal, interspecific and partial variations of berberine content in the barks. Pharmaceutics; 249-254.
- Marek R, Seckarova P, Hulova D, Marek J, Dostal J, Sklenar V. Palmatine and Berberine isolation artifacts. Journal Of Natural Products. 2003; 66: 481-486.
- Grycova L, Dostal J, Marek R. Quaternary protoberberine alkaloids. Phytochemistry. 2007; 68: 150-175.
- Rahal A, Kumar A, Singh V, Yadav B, Tiwari R, Chakrobarty S. The Interplay: Oxidative stress, pro-oxidants and oxidants. Biomedical Research International. 2014.
- Thirupurasundari C J, Padmini R, Devaraj S N. Effect of berberine on antioxidant status, ultrastructural modifications and protein bound carbohydrates in azoxymethane- induced colon cancer in rats. Journal of Chemistry Biological Int. 2009; 177: 190-195.
- Zeng X. Relationship between the clinical effects of berberine on severe congestive heart failure and its concentration in plasma studies by HPLC. Biomedical Chromatogram. 1999; 13: 442-444.
- Chi L, Peng L, Pan N, Hu X, ZhangY, The anti-atherogenic effects of berberine of foam cell formation mediated through upregulation of sirutin I. International Journal of Molecular Medicines. 2014; 34: 1087-1093.
- Cicero A, Ertek S. Berberine: Metabolic and cardiovascular effects in preclinical and clinical trials. Journal of Nutraceuticals Diet Supplement. 2009; 1: 1-10.
- Chang T Y, Li B L, Chang C C, Urano Y. Acyl-coenzyme A: Cholesterol acyltransferases. Journal of Physiology- endocrinology and metabolism. 2009; E1-E9.
- Wang Y, Yi X, Ghanam K, Zhang S, Zhao T, Zhu X. Berberine decreases cholesterol levels in rats through multiple mechanisms, including inhibition of cholesterol absorption. Mrtabolism 2014; 63: 1167-1177.
- Yin J, Gao Z, Liu, D, Liu Z, Ye J. Berberine improves glucose metabolism through induction of glycolysis. Journal of Physiology- endocrinology and metabolism. 2008; 148-156.
- Xia X, Yan J, Shen Y, Tang K, Yin J, Zhang Y. Berberine improves glucose metabolism in diabetic rat by ingibition of hepatic gluconeogenesis. 2011.
- Chen Y, Wang Y, Lin L, Zhang Y, Sun C, Lopez A. Berberine improves glucose homeostasis in streptozotocin- induced diabetic rats in association with multiple factors of insulin resistance. ISRN Endorinol. 2011; 1-8.
- Dai P, Wang J, Lin L, Zhang Y, Wang Z. Renoprotective effects of berberine as adjuvant therapy for hypertensive patients with TypeII Diabetes mellitus: Evaluation via biochemical markers and color Doppler ultrasonography. Journal of experimental and therapeutic Medicine. 2015; 10: 869-876.
- Zhao X, Zhang J, Tong N, Chen Y, Luo Y. Protective effects of berberine on Doxorubicin- induced hepatotoxicity in mice. Journal of Biological and Pharmaceutical Bulletin. 2012; 35: 796-800.
- Domitrovic R, Jakovac H, Blagojevic G. Hepatoprotective activity of berberine mediated by inhibition of TNF-α, COX-2 expression in CCl4-intoxicated mice. Toxicology. 2011; 33-43.
- Kim S, Chung J H. Berberine prevents UV-induced MMP-I and reduction of type-I procollagen expression in human dermal fibroblasts. Phytomedicine.2008; 15: 749-753.
- Yahki K, Kiso A, Zhou Y Y. Abstracts: The effects of Coptis japonica root extract and its key component, berberine on human subcutaneous adipocytes. International Journal of Cosmetic Sciences. 2010; 32: 392-395.
- Derosa G, Maffioli P, Cicero A F. Berberine on Metabolic and Cardiovascular risk factors: An analysis from preclinical evidences to clinical trials. Expert Opinion Biomolecular Theory. 2012; 12: 1113-1124.
- Fouladi R F. 2012. Aqueous extract of dried fruit of berberis vulgaris L. in acne vulgaris, a clinical trial. Journal of Dietary Supplement. 2012; 9: 253-261.
- Johnson M, Rafikhah N. Berberis vulgaris juice and acne vulgaris: a placebo-controlled study. Asian Journal of Clinical Nutrition. 2014; 6: 47-52.
- Gupta DK, Aqil M, Sultana Y. Tailoring of berberine loaded transniosomes for the management of skin cancer in mice. Journal of Drug Delivery Science and Technology. 2020; 60: 1-13.
- Torky AS, Maha MA, Abdallah AY. Novel skin penetrating berberine oleate complex capitalizing on hydrophobic ion pairing approach. International Journal of Pharmaceutics. 2018; 76-86.
- Vanti G, Wang M, Billia AR. Hydroxypropyl methylcellulose hydrogel of berberine chlorideloaded escinosomes: Dermal absorption and biocompatibility. International Journal of Biological Macromolecule. 2020; 1-29.
- Niu J, Yuan M, Chen C, Wang L, Gan Y. Berberine-Loaded Thiolated Pluronic F127 Polymeric Micelles for Improving Skin Permeation and Retention. International Journal of Nanomedicine.2020; 1-19.
- Lin H, Lim L, Choi Y. Development and in-vitro evaluation of coloaded berberine chloride and evodiamine ethosomes for treatment of melanoma. International Journal of Pharmaceutics. 2020; 1-7.
- Vanti G, Bani D, Salvatici CM, Bergonzi MC, Billia AR. Development and Percutaneous Permeation Study of Escinosomes, Escin-Based Nanovesicles Loaded with Berberine Chloride. Pharmaceutics. 2019; 1-22.
- Gull A, Ahmed S, Ahmed FS, Chandra. Hydrogel thickened microemulsion; a local cargo for the co- delivery of cinnamaldehyde and berberine to treat acne vulgaris. Journal of Drug Delivery Science and Technology. 2020; 58: 1-10
- Amato G, Grimaudo MA, Lorenzo CA, Carbone C, Musumeci T. Hyaluronan/Poly-L-lysine/Berberine Nanogels for Impaired Wound Healing. Pharmaceutics. 2020; 1-11.
- Mayangsari F, Surini S, Iswandana R. Development of transfersomal emulgel to enhance the permeation of berberine chloride for transdermal delivery. Journal of Applied Pharmaceutical Science. 2022; 12(02): 48-55.
- Awate P S, Pimple T P, Pananchery JF, Jain A S. Formulation and evaluation of berberine hcl as niosomal drug delivery system. Asian Journal of Pharmaceutical Research. 2020; 10(3).
- Rahamat U, Kumar P M, Gella S. Psoriasis: A comprehensive Review. Asian J. of Res.in Pharma. Sciences. 2019; 9(1): 29-38.
- Mahajan T, Singh N, Goyal K, Jindal S, Pandit V, Ashawat MS. Recent updates on Psoriasis: A Review. Asian Journal of Pharmaceutical research. 2022; 12(1): 3-76.
- Singh N, Sondhi S, Jindal S, Pandit V, Ashawat MS. Treatment and Management for patients with mild to severe Psoriasis: A Review. Asian Journal of Pharmaceutical Research. 2020; 10(4):286-292.
- Sondhi S, Singh N, Jindal S. Natural Remedies used in treatment of Psoriasis: A Short review. Asian Journal of Pharmaceutical Research. 2021; 11(1): 43-45.
- Sharma S, Sharma R, Goyal K, Jindal S. Potential of herbal treatment of Psoriasis: A Laconic Review. Asian Journal of Research in Pharmaceutical Sciences. 2021; 11(1): 51-57.
- Sondhi S, Singh N, Goyal K, Jindal S. Development of Topical Herbal gel of Berberine Hydrochloride for the treatment of Psoriasis. 2021; 13(1): 12-18.
- Verma D, Samal P K. Evaluation of Synergistic analgesic Activity of Berberine and Asiatic Acid in Mice. Research Journal of Pharmacy and Technology. 2020; 13(12): 6081-6085.
- Singh N, Goyal K, Sondhi S, Jindal S. Traditional and medicinal use of Barbaloin: Potential for the Management of Various Disease. 2020; 8(3): 21-30.
- Singh N, Goyal K, Sondhi S, Jindal S. Development and characterization of Barbaloin Gel for the safe and effective treatment of Psoriasis. Journal of Drug Delivery and Therapeutics. 2020; 10(5): 188-197.